Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

21 Oct 2019

Abstract excerpt

In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogenesis, these proteins are hard to target with traditional small molecule drugs due to their large, featureless...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemical Synthesis and Analysis
Share to Click Chemistry and Applications
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31636382
DOI: 10.1038/s41388-019-1056-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision medicine by designer interference peptides: applications in oncology and molecular therapeuticsPMID 31636382Read ↗

The Precision Medicine: Advancement and Transformation in Cancer TreatmentSemantic proximity Read ↗

PANCS-Inhibitors: A rapid method to directly select for protein-protein interaction inhibitorsSemantic proximity Read ↗

Strategies to target the cancer driver MYC in tumor cellsSemantic proximity Read ↗

Tailoring Peptidomimetics for Targeting Protein–Protein InteractionsSemantic proximity Read ↗

Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging OpportunitiesSemantic proximity Read ↗

Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.Semantic proximity Read ↗

Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.Semantic proximity Read ↗

Alternative approaches to target Myc for cancer treatmentSemantic proximity Read ↗

Modulating Phosphorylation by Proximity-Inducing Modalities for Cancer TherapySemantic proximity Read ↗

Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein.Semantic proximity Read ↗

Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonistsSemantic proximity Read ↗

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.